|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | Genzyme |
|---|---|
| Information provided by: | Genzyme |
| ClinicalTrials.gov Identifier: | NCT00454350 |
Purpose
This study will measure serum levels of the active Vitamin D compound that circulates in hemodialysis subjects treated with either doxercalciferol injection (Hectorol®) or Zemplar® (paricalcitol injection).
| Condition | Intervention | Phase |
|---|---|---|
|
Secondary Hyperparathyroidism |
Drug: Hectorol (doxercalciferol injection) Drug: Zemplar (Paricalcitol injection) |
Phase IV |
| Study Type: | Interventional |
| Study Design: | Treatment, Randomized, Open Label, Active Control, Crossover Assignment, Pharmacokinetics Study |
| Official Title: | A Randomized , Open-Label, Cross-over, Pharmacokinetic Study of Doxercalciferol and Paricalcitol Following Multiple Intravenous Injections in Chronic Kidney Disease Subjects on Hemodialysis |
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations
More Information
| Responsible Party: | Genzyme Corporation ( Medical Monitor ) |
| Study ID Numbers: | HECT00106 |
| Study First Received: | March 28, 2007 |
| Last Updated: | July 30, 2009 |
| ClinicalTrials.gov Identifier: | NCT00454350 History of Changes |
| Health Authority: | United States: Food and Drug Administration |
|
Hectorol (doxercalciferol injection) Zemplar (paricalcitol injection) |
|
Parathyroid Diseases Hyperparathyroidism, Secondary 1 alpha-hydroxyergocalciferol Hyperparathyroidism Growth Substances Vitamins |
Physiological Effects of Drugs Ergocalciferols Endocrine System Diseases Bone Density Conservation Agents Micronutrients Pharmacologic Actions |